 |
Managing Director. Dr. Vasant Gandhi is the Managing Director of Molecular Decisions Strategy LLC. Dr. Gandhi has broad experience in life sciences transactions and strategy through corporate development (licensing, technology transfer and strategy), alliance management, legal and commercial and development operations. He has worked on commercial strategy and deals for therapeutics (including biosimilars), diagnostics, and vaccines. Dr. Gandhi worked at Amgen Inc., as Senior Counsel, on Amgen’s molecular discovery and biotechnology licensing matters. Dr. Gandhi also served as senior counsel at Immunex Corporation where he worked on corporate transactions, including the acquisition of Immunex by Amgen and the divestiture of Leukine™ to Schering AG. He also served as VP, Strategic Operations at Abraxis (now Celgene) and EVP, Corporate Development and GC at Avesthagen and other management roles through his consulting activities. Dr. Gandhi worked at the National Institutes of Health (including the National Cancer Institute) and at business consulting and law firms. Dr. Gandhi holds advanced degrees in science, law, and business. |
| Molecular Decisions Strategies also has key strategic relationships with the following individuals whose expertise can be focused on specific engagements. |
 |
Dr. Patricia Beckmann is the founder of BioStrategy, LLC, a bioscience strategic and management consultancy. Previously, Dr. Beckmann was the President and Executive Director of the Oregon Translational Research and Development Institute. Patricia was a Kauffman Fellow at Accelerator Corporation and was Chief Scientific Officer of Homestead Clinical Corporation (now Integrated Diagnostics), an Accelerator-backed startup focusing on proteomics and biomarkers for cancer. She was responsible for biotechnology venture investment opportunities at Vulcan Capital, the investment vehicle for Microsoft co-founder Paul Allen, and was part of the original strategic team for the $100M endowed Allen Institute for Brain Sciences. Patricia held various research and management positions at Immunex Corporation and later Amgen, including Scientific Liaison for Research Administration and Law. At Immunex, her efforts resulted in the discovery and development of the drug Enbrel (2010 worldwide sales over $7B), for which she was awarded National Inventor of the Year in 2000. Patricia earned her BA in biology, chemistry and art from The Evergreen State College and her PhD in biochemistry and pharmacology from the University of Arizona, College of Medicine. She pursued postgraduate studies as a Fulbright Scholar in Sweden and as a Visiting Scientist at the National Cancer Institute in Bethesda, MD. Patricia has over 50 scientific publications and more than 40 issued US patents. |
|
|
 |
Dr. Robert Morlock is an experienced health care organization leader with over 16 years progressive experience in the U.S. and international markets. Dr. Morlock specializes in market access and reimbursement, health services research, patient reported outcomes, and pricing. He has worked in all stages of product development and has been instrumental in establishing commercialization strategies bringing novel therapies to market.Dr. Morlock specializes in market access and reimbursement, health services research, patient reported outcomes, and pricing. Robert also directed a team of pharmacoeconomic and outcomes researchers at Pfizer, Inc., led the oncology and rheumatology global health economics function for Biogen Idec and was Vice President of Pricing and Market Access at Abraxis BioScience. Robert has a PhD in economics from Wayne State University and continuing executive training from Harvard University School of Public Health and the University of Michigan Business School. |
|
|
Leave a Reply